Refocused Sophiris to switch to transrectal injection for enlarged prostate drug
This article was originally published in Scrip
Sophiris Bio will use a transrectal route of administration, rather than the transperineal route, for its lead drug PRX302 for the treatment of Benign Prostatic Hyperplasia (BPH or enlarged prostate). This follows a three-month 40-patient study which showed that a transrectal ultrasound (TRUS) guided injection directly into the prostate was well tolerated. The selection of the route of administration is another step in a substantial refocusing of the company which saw the appointment of a new CEO, Randall Woods, in mid-August, and a halt to other development projects to allow more resources to be put into the PRX302/BPH program. With its singular focus on the BPH drug, Sophiris hopes to take PRX302 into a Phase III trial later in 2012.